Nuvectis Pharma, Inc.
NVCT· Nasdaq
Released Feb 25, 2025, before the open
10-K filed Feb 25, 2025, 56 days after period end · 0001558370-25-001496
derived · Computed from the longer spans the company filed.
| Metric | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures |
|---|---|---|---|---|
| Net Income | -$6.25M | -$6.62M | -$6.70M | -$2.26M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Nuvectis Pharma, Inc. · CIK 1875558 · Engraved from SEC EDGAR
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
ended Dec 31, 2024 · filed Feb 25, 2025 · 56 d after period end
7.1% from the close of Feb 24, 2025 to the close of Feb 25, 2025, the first after the release.